Mark Opal

Mark Opal, Ph.D., is the National Director - Field Medical Rare Disease at Pfizer, focusing on Sickle Cell Disease. Previously, they served as Director of Medical Science Liaisons at Global Blood Therapeutics and held the position of Medical Director at SAGE Therapeutics. Their background includes roles at Collegium Pharmaceutical and Mallinckrodt Pharmaceuticals, where they worked in pain management and autoimmune diseases, respectively. Mark also boasts a rich educational foundation, having earned a Ph.D. in Neurobiology from the University of Chicago, where they made significant contributions to understanding antidepressant responses.